Weill Medical College of Cornell University
Company
Weill Medical College of Cornell University develops one asset, in phase 1 (LX1001 in Alzheimer's disease). Mostly gene therapy acting on lipid and ceramide metabolism, APOE and proteostasis.
- 1
- Asset
- Furthest
- Phase 1
- 86
- Trials
- 0
- Signals
Pipeline
1AAVrh10 gene therapy expressing human APOE2 to convert CSF phenotype in APOE4 homozygotes
Phase 1, Gene therapy, Lipid and ceramide metabolism, APOE, Alzheimer's disease, early-onset Alzheimer's disease, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials111
- Integrity notices10
- Similar companies6
Updated 12 Oct 2026 · 113 sources